Breaking Down Mayinglong Pharmaceutical Group Co., LTD. Financial Health: Key Insights for Investors

Curious whether Mayinglong Pharmaceutical Group Co., Ltd. (600993.SS) is a resilient play or an overvalued healthcare name? In H1 2025 the firm recorded revenue of about CNY 1.95 billion (TTM revenue CNY 3.75 billion), while net income climbed to CNY 343.22 million in the same period-a 10.04% year‑over‑year rise-backed by a trailing net profit margin of 14.25% and an operating margin of 23.91%; liquidity looks robust with CNY 2.65 billion in cash and a net cash position of CNY 2.55 billion, total assets of CNY 5.63 billion versus liabilities of CNY 1.36 billion (debt‑to‑equity ~0.02), operating cash flow (TTM) of CNY 630.12 million, and an interest coverage ratio of 70.52 that together support a current ratio of 5.02 and quick ratio of 4.47-valuation metrics include a market cap of CNY 12.24 billion, trailing P/E of 20.70 (forward P/E 18.24), P/S 3.27 and P/B 2.68, while growth vectors span anorectal specialty hospitals, expanded products (ophthalmology, dermatology, probiotics), and R&D investment amid industry risks like regulatory changes, raw material cost swings and competitive pressure.

Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) - Revenue Analysis

• H1 2025 revenue: CNY 1.95 billion (+1.11% YoY)
• TTM revenue: CNY 3.75 billion (+9.50% YoY)
• FY 2024 revenue: CNY 3.73 billion (+18.85% YoY)
• Revenue per employee: ~CNY 1.41 million (2,654 employees)
• Market capitalization: CNY 12.24 billion
• Price-to-Sales (P/S): 3.27
• Price-to-Book (P/B): 2.68

Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) - Profitability Metrics

• Net income (1H 2025): CNY 343.22 million - a 10.04% increase from CNY 311.91 million in 1H 2024.
• Trailing twelve months (TTM) net profit margin: 14.25% - indicating effective cost and margin management.
• Operating margin (TTM): 23.91% - reflecting high operational efficiency in core activities.
• Return on assets (ROA): 6.96% - showing solid asset utilization.
• Return on equity (ROE): 13.13% - signalling effective use of shareholder capital.
• Earnings per share (EPS, TTM): CNY 1.33; trailing P/E ratio: 20.70.
• Dividend yield: 2.15%; ex-dividend date: August 8, 2025.

Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) Debt vs. Equity Structure

• Total assets: CNY 5.63 billion
• Total liabilities: CNY 1.36 billion
• Reported debt-to-equity ratio: 0.02

• High cash buffer: CNY 2.65 billion in cash/equivalents provides flexibility for capex, M&A or downturns.
• Low leverage: a reported debt-to-equity of 0.02 and a multi-year improvement in leverage metrics point to minimal reliance on external debt.
• Strong liquidity and short-term health: current ratio of 5.02 signals ample short-term asset coverage of liabilities.
• Robust coverage: operating cash flow (TTM) of CNY 630.12 million comfortably covers capital expenditures; interest coverage at 70.52 implies negligible default risk on interest payments.

Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) - Liquidity and Solvency

• Current ratio: 5.02 - indicates strong short-term financial health and a significant buffer to meet current liabilities.
• Quick ratio: 4.47 - suggests the company holds sufficient liquid assets (cash and equivalents, marketable securities, receivables) to cover short-term obligations without relying on inventory sales.
• Net cash position: CNY 2.55 billion - a meaningful liquidity cushion that reduces refinancing and solvency risk.
• Operating cash flow (TTM): CNY 630.12 million - positive and enough to comfortably cover routine capital expenditures and support working capital needs.
• Interest coverage ratio: 70.52 - reflects an extremely strong ability to meet interest expenses from operating earnings.

• Balance-sheet resilience: A net cash position of CNY 2.55 billion combined with operating cash flow of CNY 630.12 million (TTM) gives Mayinglong flexibility to absorb shocks and pursue strategic uses of capital.
• Leverage and financing risk: Extremely high interest coverage (70.52) and effectively positive net debt profile reduce refinancing and credit risk compared with peers that carry higher leverage.
• Working-capital dynamics: Current and quick ratios (5.02 and 4.47) suggest low near-term liquidity pressure; investors should monitor receivables/inventory trends to ensure ratios reflect operating performance rather than seasonal timing.

Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) - Valuation Analysis

• Trailing P/E: 20.70 - current investors pay CNY 20.70 for each CNY 1 of trailing earnings.
• Forward P/E: 18.24 - implied modest earnings growth or margin improvement priced in by the market.
• P/B: 2.68 - stock trades at about 2.7x its book value, a moderate premium to net assets.
• EV/EBITDA: 14.09 - valuation relative to operating cash profits consistent with mid-cycle pharma peers.
• EV/Revenue: 2.51 - the enterprise is valued at 2.51x annual revenue.
• Market Cap: CNY 12.24 billion; P/S: 3.27 - investors pay 3.27x the company's revenues.

Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) - Risk Factors

Mayinglong Pharmaceutical Group operates in a dynamic, highly regulated sector. Below are the primary risks that can materially affect its financial health, illustrated with key financial metrics to contextualize exposure.

• Regulatory and reimbursement risk: changes in drug approval rules, pricing controls and tighter oversight of medical insurance funds can compress revenue and delay product launches. For context, the company's reported dependence on domestic retail and hospital channels means reimbursement policy shifts can affect up to an estimated 35-55% of product sales.
• Competitive pressure and need for continual innovation: maintaining market share requires sustained R&D investment and product lifecycle management. Mayinglong's approximate R&D spend is ~1.2-2.0% of revenue in recent years, lower than many mid-sized pharma peers, which raises competitive vulnerability.
• Raw material and input cost volatility: fluctuations in prices for active pharmaceutical ingredients (APIs), packaging and logistics can squeeze margins-gross margin sensitivity is notable given labor and input cost increases. A 10% rise in key API costs could reduce operating margin by an estimated ~1-2 percentage points.
• Shifts in consumer preferences and public health trends: as OTC and topical product demand changes (e.g., population aging vs. younger consumers), revenue mix may shift faster than the company can adapt.
• Macroeconomic and consumption risk: economic slowdowns can reduce discretionary healthcare spending, affecting OTC and retailer sales channels. A mild GDP contraction (1-2%) historically correlates with single-digit declines in consumer healthcare sales.
• Currency and international exposure: although primarily domestic, any export or cross-border procurement exposes the company to RMB exchange rate fluctuations. A 5% depreciation of RMB against the USD/EUR could raise import costs and compress margins for sourced APIs.

• Regulatory timing risk: product approvals and hospital listing cycles can cause lumpy revenue recognition; delayed approvals can push out projected sales by quarters or years.
• Margin compression risk: combined effects of pricing pressure, reimbursement cuts and input-cost inflation can materially reduce EBITDA if not offset by efficiency gains.
• Product concentration risk: flagship lines (topicals/OTC) represent a significant portion of sales-loss of market share or negative publicity for a core product could disproportionately impact revenue.
• Supply-chain and procurement risk: reliance on third-party API suppliers exposes the company to disruptions, raw material shortage spikes and quality-control incidents.
• Currency/FX and international receivables risk: invoices and procurement in foreign currencies can affect cash flows; hedging practices (if limited) increase sensitivity to exchange-rate moves.
• Macroeconomic and consumer demand risk: slower household spending or a shift toward alternative therapies/brands could lower demand for traditional products.

Risk-monitoring indicators investors should track include quarterly gross margin trends, R&D spend as a percent of revenue, inventory turnover, days receivable, regulatory approvals pipeline, and exposure to reimbursement changes.

Exploring Mayinglong Pharmaceutical Group Co., LTD. Investor Profile: Who's Buying and Why?

Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) - Growth Opportunities

• Core franchise strength: long-standing brand recognition in anorectal pharmaceuticals creates a high barrier to entry in its niche and supports premium pricing for established products.
• Service expansion: proprietary anorectal specialty hospitals and diagnostic centers improve patient capture, treatment compliance and cross-selling of medicines and consumables.
• Product diversification: extension into ophthalmology, dermatology and functional probiotics reduces single-category exposure and taps larger market pools.
• Manufacturing & quality: investment in advanced manufacturing tech and enhanced quality-control systems is intended to raise capacity, lower per-unit cost and support export/commercial scale-up.
• Consumer hygiene upgrades: launch of upgraded hygiene product lines caters to rising hygiene awareness and recurring-consumption revenue streams.

• Integrated care model: owning treatment facilities shortens the path from diagnosis to repeat purchase and enables real-world evidence collection to support product claims.
• Channel diversification: presence across hospitals, clinics, retail pharmacies and e-commerce mitigates single-channel risks and captures shifting consumer behavior.
• Adjacency moves: ophthalmology and dermatology markets are substantially larger than the anorectal niche; even modest share gains materially increase addressable revenue.
• Product lifecycle management: upgrading hygiene SKUs and adding recurrent-consumption products (e.g., probiotics) improves recurring revenue and customer lifetime value.
• Quality & compliance: enhanced manufacturing capability facilitates entry into regulated hospital tenders and potential export markets, supporting higher-margin institutional sales.

• R&D productivity: pipeline progression timelines and clinical readouts in ophthalmology/dermatology will signal scalability beyond the core franchise.
• Hospital network economics: revenue per bed/clinic, patient throughput and cross-sell rates determine whether vertical integration is accretive.
• Margin trajectory: improvements from scale, process automation and product mix shift (more OTC/consumer goods vs. single-shot pharmaceuticals) will drive EBITDA expansion.
• Regulatory & quality milestones: successful GMP upgrades and approvals for new therapeutic indications influence market access and institutional procurement.
• New product adoption: sales ramp for probiotics and upgraded hygiene products, especially through e-commerce, will reflect consumer acceptance and marketing effectiveness.

• Sales mix by channel (hospital vs. retail vs. e-commerce)
• New product contribution to revenue (%)
• R&D spend and pipeline milestones
• Occupancy/utilization and ARPU metrics for specialty centers
• Gross margin and operating margin trend lines